Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 4.33%154.810.0%$1863.66m
NVAXNovavax, Inc. 4.39%231.2392.9%$1423.06m
OCGNOcugen, Inc. 36.88%10.950.0%$1213.37m
AMGNAmgen, Inc. -1.14%224.921.3%$594.80m
ILMNIllumina, Inc. -1.45%439.413.5%$530.13m
REGNRegeneron Pharmaceuticals, Inc. -0.58%450.572.7%$522.91m
VRTXVertex Pharmaceuticals, Inc. -0.20%212.551.9%$515.41m
GILDGilead Sciences, Inc. -2.21%61.401.0%$485.52m
BIIBBiogen, Inc. -1.58%272.881.7%$380.18m
BNGOBioNano Genomics, Inc. -2.89%9.730.0%$374.38m
ALXNAlexion Pharmaceuticals, Inc. -0.59%152.752.0%$371.25m
CRSPCRISPR Therapeutics AG -1.25%125.690.6%$292.02m
EXASEXACT Sciences Corp. 3.67%136.1218.4%$252.07m
SGENSeagen Inc. 0.68%151.115.8%$212.33m
VXRTVaxart, Inc. -4.67%7.150.0%$210.57m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.